Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 461Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Breast Neoplasms 162Triple Negative Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 146Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Endometrial Neoplasms 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × pembrolizumab × Clear all
NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06708858 2024-11-27

Phase â…¡ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡